Special Episode: Oncology After COVID-19
In season 2, episode 4 of “Targeted Talks,” Benjamin O. Anderson, MD, FACS, discussed the lessons learned from the COVID-19 pandemic, and preparation for a post-COVID America.
In season 2, episode 4 of “Targeted Talks,” Benjamin O. Anderson, MD, FACS, of the World Health Organization and Fred Hutchinson Cancer Research Center joins our host for a recap interview around a recent Targeted Oncology webinar, “Lessons Learned in Pathology and Oncology From the COVID-19 Pandemic.”
According to Anderson, the COVID-19 pandemic revealed great opportunities within our health care system, like telemedicine, which has increased since the pandemic began and is likely to continue in the future. The pandemic also revealed some weaknesses within the health care infrastructure that will have to be addressed after the pandemic as a method of readiness for future crises.
Part of improving the United States health care system, according to Anderson, is understanding that different patient populations have different resources and coming up with a plan that works for all groups.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
